Genentech, Inc.

Curis, Inc.

Janssen Pharmaceutica Nv

F. Hoffmann-La Roche Ag

Vertex Pharmaceuticals, Inc.

Other

Merck + Co., Inc.

Genetech, Inc.

Almac Discovery Limited

Evotec Oai

Curtis, Inc.

The Institute Of Cancer Research: Royal Cancer Hospital

Stephen Colin Price

Robert Andrew Heald

Edward Andrew Boyd

Oivin M Guicherit

Alan G Olivero

Adrian Folkes

Steven Huy Do

Steven T Staben

Aleksandr Kolesnikov

Chudi Obioma Ndubaku

Timothy Heffron

Nicole Blaquiere

Danette Dudley

John Gary Montana

Lee L Rubin

Anthony David Baxter

George Hynd

Samuel Edward Mann

Patrizia Tisselli

Lan Wang

Mark Jones

John Harry Alexander Stibbard

Janusz Jozef Kulagowski

Pascal Pierre Alexandre Savy

Calum MacLeod

Timothy Colin Hancox

Neil Anthony Pegg

Daniel P Sutherlin

Brian Salvatore Safina

Eileen Mary Seward

Hazel Joan Dyke

Richard A Goldsmith

Terry Aaron Panchal

Calum Macleod

Zachary Kevin Sweeney

Matthew C Lucas

Maria Frank-Kamenetsky

Wendy Lee

Georgette M Castanedo

Alan John Nadin

Jeffrey A Porter

Karen Williams

Toby Jonathan Blench

Shirley Ann Brunton

Jeffery Porter

David Goldstein

Rama Kondru

Wylie Palmer

Colin H Mackinnon

Roger D Tung

Michael Robin Hale

Eric Steven Furfine

Bryan K Chan

BinQing Wei

David Edward Clark

Mark Edward Zak

Istvan Kaldor

Mark S Stanley

Andrew Spaltenstein

Stephen Joseph Shuttleworth

Mandy Christine Beswick

Ashley Nicholas Jarvis

Joanne Frances Mary Hewitt

Philip Jackson

Fabien Jean Ghislain Roussel

Gregory J Kaczorowski

Tim Heffron

Binqing Wei

Vicente Samano

Stewart James Baker

Liang Bao

John Franklin Miller

Elsa Amandine Dechaux

Wayne Carl Schairer

Paul John Goldsmith

Robin David Wilkes

Michael Stephen Brieger

Joseph P Lyssikatos

Timothy Harrison

Michael H Fisher

William H Parsons

Peter T Meinke

Emanuela Gancia

Simon Charles Goodacre

Richard Leonard Elliott

Maria L Garcia

Ronald George Sherrill

Frank Burkamp

Colin O'Dowd

Sukhjit Sohal

James Samuel Shane Rountree

Bohdan Waszkowycz

Lixin Zhang

Graham Peter Trevitt

Judith Helen Boyd, Legal Representative

Pascal Savy

Peter Hewitt

Jahusz Jozef Kulagowski

John Stibbard

Janusz Josef Kulagowski

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-&#x3ba;B-inducing kinase (NIK&#x2014;also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

Pyrazolopyrimidine derivatives as NIK inhibitors

Thienopyrimidine derivatives as NIK inhibitors

Compounds as NIK inhibitors

[object Object]

Pyrazole derivatives as NIK inhibitors

Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxazepin PI3K inhibitor compounds and methods of use

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-&#x3ba;B-inducing kinase (NIK&#x2014;also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders. 

3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer

Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and where (i) Xis N and Xis S, (ii) Xis S and Xis N, (iii) Xis CRand Xis S, (iv) Xis S and Xis CR; (v) Xis NRand Xis N, (vi) Xis N and Xis NR, (vii) Xis CRand Xis O, (viii) Xis O and Xis CR, (ix) Xis CRand Xis C(R), (x) Xis C(R)and Xis CR; (xi) Xis N and Xis O, or (xii) Xis O and Xis N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxepin PI3K inhibitor compounds and methods of use

The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS.and. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.

Small organic molecule regulators of cell proliferation

The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. 

Bicyclic heterocycles as MEK kinase inhibitors

Growing community of inventors

Essex, United Kingdom

Stephen Colin Price